ArticleBriefings in bioinformatics2026
Pathogenicity prediction for noncanonical splice-altering variants based on multimodal feature fusion.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Splice-altering variants (SAVs) are the second most prevalent class of pathogenic genetic variants and are strongly associated with the occurrence and development of various diseases. However, current computational tools exhibit limited predictive capability beyond canonical GT-AG splice sites, making accurate assessment of noncanonical SAV pathogenicity a considerable challenge. To address this limitation, we developed MOSAIC (multimodal feature fusion for noncanonical splice-altering variants pathogenicity prediction), a deep learning framework designed for precise assessment of noncanonical SAV pathogenicity. MOSAIC integrates long-range contextual signals derived from a pretrained DNA language model, local sequence features captured from multi-scale convolutional neural networks, and functional annotations. By employing a transformer encoder and a gated fusion module, the model adaptively integrates these multimodal features. Benchmarking across multiple independent datasets demonstrated that MOSAIC consistently outperforms existing state-of-the-art methods, such as CADD and SpliceAI. It remains highly accurate and robust when evaluated on rare variants, gene-independent contexts, and the largest subset where all comparative methods yielded outputs. Furthermore, feature importance analysis revealed that long-range dependencies in DNA sequences and transformer-based integration were critical contributors to model performance. Interpretability analyses indicated that MOSAIC could identify key regulatory sequence motifs associated with transcription factors and RNA-binding proteins, offering mechanistic insight into how noncanonical SAVs disrupt splicing regulation and contribute to pathogenic processes. Overall, MOSAIC offers an accurate and interpretable framework for predicting the pathogenicity of noncanonical SAVs, thereby serving as a dependable computational tool for genetic diagnostics and precision medicine applications. MOSAIC source code and data are available at https://github.com/Lilab-genomics/MOSAIC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.